NO318782B1 - Terapeutiske biarylderivate, samt fremgangsmate for fremstilling og anvendelse derav og farmasoytisk preparat - Google Patents

Terapeutiske biarylderivate, samt fremgangsmate for fremstilling og anvendelse derav og farmasoytisk preparat Download PDF

Info

Publication number
NO318782B1
NO318782B1 NO20006319A NO20006319A NO318782B1 NO 318782 B1 NO318782 B1 NO 318782B1 NO 20006319 A NO20006319 A NO 20006319A NO 20006319 A NO20006319 A NO 20006319A NO 318782 B1 NO318782 B1 NO 318782B1
Authority
NO
Norway
Prior art keywords
amino
chlorophenyl
ethyl
hydroxyethyl
biphenyl
Prior art date
Application number
NO20006319A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006319L (no
NO20006319D0 (no
Inventor
Kelly Horne Donaldson
Barry George Shearer
David Edward Uehling
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20006319D0 publication Critical patent/NO20006319D0/no
Publication of NO20006319L publication Critical patent/NO20006319L/no
Publication of NO318782B1 publication Critical patent/NO318782B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20006319A 1998-06-13 2000-12-12 Terapeutiske biarylderivate, samt fremgangsmate for fremstilling og anvendelse derav og farmasoytisk preparat NO318782B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812709.5A GB9812709D0 (en) 1998-06-13 1998-06-13 Chemical compounds
PCT/EP1999/003958 WO1999065877A1 (en) 1998-06-13 1999-06-09 Therapeutic biaryl derivatives

Publications (3)

Publication Number Publication Date
NO20006319D0 NO20006319D0 (no) 2000-12-12
NO20006319L NO20006319L (no) 2001-02-09
NO318782B1 true NO318782B1 (no) 2005-05-09

Family

ID=10833658

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006319A NO318782B1 (no) 1998-06-13 2000-12-12 Terapeutiske biarylderivate, samt fremgangsmate for fremstilling og anvendelse derav og farmasoytisk preparat

Country Status (38)

Country Link
US (1) US6251925B1 (sk)
EP (1) EP1087943B1 (sk)
JP (1) JP3471754B2 (sk)
KR (1) KR100415877B1 (sk)
CN (1) CN1214008C (sk)
AP (1) AP1687A (sk)
AR (1) AR029301A1 (sk)
AT (1) ATE302189T1 (sk)
AU (1) AU753004B2 (sk)
BR (1) BR9911182B1 (sk)
CA (1) CA2334713C (sk)
CO (1) CO5060482A1 (sk)
CZ (1) CZ299172B6 (sk)
DE (1) DE69926752T2 (sk)
DK (1) DK1087943T3 (sk)
EA (1) EA003641B1 (sk)
EE (1) EE04435B1 (sk)
EG (1) EG23856A (sk)
ES (1) ES2245107T3 (sk)
GB (1) GB9812709D0 (sk)
HK (1) HK1034253A1 (sk)
HR (1) HRP20000854B1 (sk)
HU (1) HUP0102668A3 (sk)
ID (1) ID27841A (sk)
IL (2) IL140219A0 (sk)
IS (1) IS2277B (sk)
MY (1) MY119542A (sk)
NO (1) NO318782B1 (sk)
NZ (1) NZ508805A (sk)
PE (1) PE20000726A1 (sk)
PL (1) PL196943B1 (sk)
RS (1) RS49921B (sk)
SI (1) SI1087943T1 (sk)
SK (1) SK286256B6 (sk)
TR (1) TR200100299T2 (sk)
TW (1) TWI244471B (sk)
WO (1) WO1999065877A1 (sk)
ZA (1) ZA200007417B (sk)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9929118D0 (en) * 1999-12-10 2000-02-02 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) * 1999-12-11 2000-02-02 Glaxo Group Ltd Process
DE10005150A1 (de) * 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
CA2423792A1 (en) 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
US7034053B2 (en) 2001-01-31 2006-04-25 Smithkline Beecham Corporation Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors
GB0102408D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Chemical compounds
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
EP1236723A1 (en) * 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
AR035858A1 (es) 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
JP2005526696A (ja) 2001-09-14 2005-09-08 バイエル・フアーマシユーチカルズ・コーポレーシヨン ベータ−３アドレナリン受容体アゴニストとして有用なベンゾフランおよびジヒドロベンゾフラン誘導体
WO2003072571A1 (en) * 2002-02-27 2003-09-04 Pfizer Products Inc. Salt of a pyridyl ethanolamine derivative and its use as a beta-3-adrenergic receptor agonist
DOP2003000587A (es) * 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
MXPA04008298A (es) 2002-02-27 2004-11-26 Pfizer Prod Inc Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico.
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
EP1546105A1 (en) * 2002-07-17 2005-06-29 Lek Pharmaceutical and Chemical Co. D.D. Novel derivatives of pyridylethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, processes for their preparation, and pharmaceutical compositions containing them
GB0220730D0 (en) * 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
US8030336B2 (en) * 2002-12-13 2011-10-04 Ym Biosciences Australia Pty Ltd Nicotinamide-based kinase inhibitors
CN100418944C (zh) * 2003-02-14 2008-09-17 橘生药品工业株式会社 氨基醇衍生物、含有所述氨基醇衍生物的药物组合物及其应用
AU2004212381B2 (en) 2003-02-14 2008-08-21 Kissei Pharmaceutical Co., Ltd. Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof
JP4644601B2 (ja) 2003-10-24 2011-03-02 キッセイ薬品工業株式会社 アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途
MXPA06007173A (es) 2003-12-23 2006-08-23 Astellas Pharma Inc Derivados de aminoalcohol.
US7915309B2 (en) * 2007-06-20 2011-03-29 Protia, Llc Deuterium-enriched oseltamivir
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US8778998B2 (en) 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
TW201208667A (en) 2010-08-03 2012-03-01 Altherx Inc Pharmaceutical combinations
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
AR089957A1 (es) 2012-02-09 2014-10-01 Altherx Inc Combinaciones farmaceuticas, combinaciones sinergicas
WO2014108449A1 (en) 2013-01-08 2014-07-17 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
EP3226849A4 (en) 2014-12-03 2018-05-09 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
DK3365321T3 (da) 2015-10-23 2024-01-15 B3Ar Therapeutics Inc Solabegron-zwitterion og anvendelser deraf
CA3064989A1 (en) 2017-06-06 2018-12-13 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
GB8519154D0 (en) * 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
DE3934436A1 (de) 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5061727A (en) * 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
WO1995033724A1 (en) * 1994-06-09 1995-12-14 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists

Also Published As

Publication number Publication date
BR9911182B1 (pt) 2010-09-08
EP1087943B1 (en) 2005-08-17
CZ20004648A3 (en) 2001-06-13
KR100415877B1 (ko) 2004-01-24
HUP0102668A3 (en) 2002-11-28
DE69926752T2 (de) 2006-02-02
ES2245107T3 (es) 2005-12-16
HRP20000854A2 (en) 2001-12-31
CZ299172B6 (cs) 2008-05-07
CN1312800A (zh) 2001-09-12
ZA200007417B (en) 2001-12-12
TWI244471B (en) 2005-12-01
EA200001172A1 (ru) 2001-08-27
US6251925B1 (en) 2001-06-26
CA2334713A1 (en) 1999-12-23
ATE302189T1 (de) 2005-09-15
AR029301A1 (es) 2003-06-25
CO5060482A1 (es) 2001-07-30
EE04435B1 (et) 2005-02-15
IS5760A (is) 2000-12-08
NO20006319L (no) 2001-02-09
MY119542A (en) 2005-06-30
JP2002518374A (ja) 2002-06-25
AU753004B2 (en) 2002-10-03
GB9812709D0 (en) 1998-08-12
IL140219A (en) 2006-07-05
CA2334713C (en) 2006-01-17
ID27841A (id) 2001-04-26
HK1034253A1 (en) 2001-10-19
DK1087943T3 (da) 2005-12-12
SK286256B6 (sk) 2008-06-06
AP2001002028A0 (en) 2001-03-31
HRP20000854B1 (en) 2006-05-31
SI1087943T1 (sl) 2005-12-31
CN1214008C (zh) 2005-08-10
KR20010052791A (ko) 2001-06-25
YU79200A (sh) 2003-01-31
WO1999065877A1 (en) 1999-12-23
PL196943B1 (pl) 2008-02-29
SK19082000A3 (sk) 2001-09-11
EP1087943A1 (en) 2001-04-04
NZ508805A (en) 2003-08-29
HUP0102668A2 (hu) 2001-12-28
NO20006319D0 (no) 2000-12-12
AP1687A (en) 2006-12-04
PE20000726A1 (es) 2000-08-24
IL140219A0 (en) 2002-02-10
RS49921B (sr) 2008-09-29
IS2277B (is) 2007-09-15
EG23856A (en) 2007-11-11
TR200100299T2 (tr) 2001-06-21
PL344865A1 (en) 2001-11-19
BR9911182A (pt) 2001-03-13
DE69926752D1 (de) 2005-09-22
EA003641B1 (ru) 2003-08-28
AU4510399A (en) 2000-01-05
JP3471754B2 (ja) 2003-12-02
EE200000744A (et) 2002-04-15

Similar Documents

Publication Publication Date Title
NO318782B1 (no) Terapeutiske biarylderivate, samt fremgangsmate for fremstilling og anvendelse derav og farmasoytisk preparat
JP2000516593A (ja) 糖尿病及び肥満症の治療に用いられる選択的β▲下３▼作動物質としての置換スルホンアミド
CA2693552A1 (en) Pyridone compound
EP2094662A1 (en) Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents
EP1984340A1 (en) Anthranilamide/2-amino-heteroarene carboxamide derivatives
EA025164B1 (ru) Соединение гуанидинобензойной кислоты
JP2003525882A (ja) アミノアルコール誘導体
RU2169141C2 (ru) Производные фенилалкилкарбоновой кислоты и фармацевтическая композиция на их основе
US7241784B2 (en) Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient
WO2007005774A2 (en) Novel derivatives of amino acids for treatment of obesity and related disorders
KR19990076688A (ko) 생물학적으로 활성인 벤조티아졸론 에탄아민
CN116829532A (zh) 经取代的环己烷甲酰胺、它们的制备和它们的治疗应用
MXPA00012389A (en) Therapeutic biaryl derivatives
EP1366033B1 (en) Chemical compounds
WO1998043953A1 (en) Naphthalenesulphonic or carboxylic acids and their use as atypical beta-adrenoceptor agonists
TW202241845A (zh) 經取代的環己烷甲醯胺、其製備方法及其治療用途
WO2001042217A1 (en) Beta-3 adrenoceptor agonists
EA046966B1 (ru) Соединения
JPH1135534A (ja) フェノキシ酢酸誘導体

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees